The U.S. Department of Defense has released detailed instructions for a new mandatory testosterone deficiency screening policy applicable to active-duty and reserve service members aged 30 and above. This directive follows an announcement made in July by U.S. Secretary of Defense Pete Hegseth. Effective immediately, the guidance sets forth standardized screening and treatment protocols for both male and female service members with the aim of enhancing military readiness through the identification and management of hormonal and energy-related issues.
Hegseth, a proponent of testosterone use, introduced the mandate last month, prompting discussions among experts regarding the scientific rationale behind such a policy. The U.S. Food and Drug Administration is scheduled to convene a panel of experts in mid-September to deliberate on the medical application of testosterone.
Under the new guidelines, men aged 30 and above will undergo compulsory testosterone blood tests, while younger men will be tested upon request or if healthcare providers detect concerning symptoms. For women, routine testosterone blood tests are not mandated, but screening for fatigue and irregular menstrual cycles, which can be linked to hormonal imbalances and conditions like low-energy availability and relative energy deficiency in sport, is recommended.
The directive outlines circumstances in which off-label testosterone prescription for women is deemed appropriate, particularly for postmenopausal women experiencing significantly reduced sexual desire. Some medical professionals have expressed apprehension that widespread testosterone testing may lead to unnecessary or potentially harmful treatment, citing insufficient evidence to support the notion that universal screening for low testosterone among military personnel would enhance U.S. combat readiness.
